Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 51,566

Document Document Title
WO/2016/161094A1
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or asso...  
WO/2016/151476A1
Disclosed herein are methods and compositions comprising adherent stromal cells.  
WO/2016/152150A1
The purpose of the invention is to provide recombinant animal serum albumin that is safe and can be mass produced and can also serve as a substitute for animal serum albumin from blood. Another purpose of the invention is to provide hemo...  
WO/2016/153065A1
A method for producing a DHA-containing glyceride-containing composition, said method including a step for obtaining a DHA-containing glyceride composition by conducting an esterification reaction by causing a lipase to act on starting m...  
WO/2016/153072A1
A blood clotting agent solution that contains, as an active ingredient, a liquid blood embolic protein intrinsic composition E2P capable of promoting and accelerating blood clotting, said liquid blood embolic protein intrinsic compositio...  
WO/2016/152965A1
The purpose of the present invention is to provide a highly safe agent for improving hypoalbuminemia, it being possible to administer the agent orally. The present invention provides an agent for improving hypoalbuminemia, the agent cont...  
WO/2016/149615A1
Disclosed herein are polypeptides comprising an amino acid sequence of {[VPGVG]4IPGVG}n, wherein n is an integer greater than 1. The polypeptides can be crosslinked to from biocompatible hydrogels with tunable and desirable mechanical pr...  
WO/2016/146604A1
The invention relates to 7-{4-[(2S)-2-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}ami no)-3-(phenylamino)-3-oxopropyl]phenyl}-6-methyl-4-oxo-l,4-d ihydroquinoline-3-carboxylic acid derivatives as factor Xla inhibitors for the treatment o...  
WO/2016/148227A1
The invention relates to a pharmaceutical composition containing a compound represented by formula (1) or a salt thereof.  
WO/2016/149126A1
Provided are therapeutic methods for treating a patient with lymphedema, or prophylactically treating an individual susceptible to lymphedema, by inhibiting synthesis activity of leukotriene B4.  
WO/2016/147040A1
The object of the invention is a pharmaceutical composition comprising a therapeutically effective amount of folic acid and (6S)-5-methyltetrahydrofolic acid glucosamine salt for the use in prophylaxis of neural tube defects in children ...  
WO/2016/146606A1
The invention relates to substituted oxo-pyridine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicaments for treating and/or preventing diseases, especially diseases of the card...  
WO/2016/148081A1
The present invention relates to a novel means for treating myelodysplastic syndromes, aplastic anemia or acute leukemia, characterized by comprising a combination of an adrenal corticosteroid and clarithromycin. More specifically, the p...  
WO/2016/144995A1
Provided are compositions that include a platelet-activating factor antagonist, pharmaceutical compositions including the platelet-activating factor antagonist, methods of treating a modulating the proliferation of a glioma or a patholog...  
WO/2016/144829A1
This invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and DF-1176-178.  
WO/2016/141889A1
Provided are a novel triazolopyrimidine derivative represented by formula II, crystal form and preparation method thereof, and use thereof in the preparation of medicine for resisting coagulation and thrombus, treating or preventing cere...  
WO/2016/141325A1
The present disclosure is directed to blood clotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same.  
WO/2016/138199A1
The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2,R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisome...  
WO/2016/137108A1
The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a meth...  
WO/2016/136933A1
A pharmaceutical composition for treating IL-6-related diseases having as an active ingredient an IL-6 inhibitor, wherein the pharmaceutical composition is administered as usual after a short-interval dosing period where the same dose as...  
WO/2016/134450A1
The present invention provides imidazopyridazine compounds or imidazothiadiazole compounds of Formula I having the structure: (I) wherein X1, X2, X3, X4, X5, Y, W, R1, R2, R3, R4, R5 and (II) are as defined herein, or a stereoisomer, tau...  
WO/2016/138301A1
The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody...  
WO/2016/135171A1
The present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt thereof in combination with dabigatran or a pharmaceutically acceptable salt or polymorph and at least one pharmac...  
WO/2016/131896A1
The present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt thereof in combination with rivaroxaban and at least one pharmaceutically acceptable excipient.  
WO/2016/131321A1
The use of reduced nicotinamide adenine dinucleotide phosphate (NADPH) in preparing medicines for the treatment or prevention of cardiovascular and cerebrovascular diseases, and medicines for the treatment or prevention of cardiovascular...  
WO/2016/133135A1
One aspect of the present invention provides a medical composition containing, as active ingredients, hyaluronic acid and polyphosphoric acid that forms a complex with calcium.  
WO/2016/127358A1
Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxi...  
WO/2016/129593A1
Provided is an agent for enhancing and/or maintaining platelet function, said agent comprising a component that is contained in supernatant I obtained by human plasma fractionation using the Cohn method but not in supernatant V.  
WO/2016/127057A1
The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing mod...  
WO/2016/124939A1
The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The pr...  
WO/2016/120432A1
The invention relates to certain compounds that are inducers of Heat shock 70 kDa protein 1A/1B (HSPA1A/B) and their use for anticoagulation therapy; and to a method for anticoagulation therapy that comprises the administration of one of...  
WO/2016/119085A1
Disclosed is an application of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetics and skin care products for maintaining self-renewal and pluripotency of stem cells. The ste...  
WO/2016/118043A1
The invention relates to the field of medicine, and specifically to agents used to stop bleeding. A hemostatic agent in the form of polyiminium methanediamine chloride of the general formula, where: n=1-20, m=1-10, and n x m ≥ 88. T...  
WO/2016/118715A1
Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a ...  
WO/2016/116942A1
The present invention relates to a novel synergistically active pharmaceutical compound, such as a supramolecular complex or an adduct or a co-crystal, comprising Ticagrelor with salts of aspirin (acetyl salicylic acid), preferably with ...  
WO/2016/118028A1
A fluid composition containing a source of iron in non-ionic form and the vehicle, characterised in that it consists of elemental iron with an average particle size from 7 to 10 micrometres and preferable particle size distribution with ...  
WO/2016/114818A1
The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical...  
WO/2016/115057A1
Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor.  
WO/2016/115535A1
The present disclosure relates to improved methods for the preparation and platelet products for administration to subjects in need thereof  
WO/2016/111357A1
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...  
WO/2016/111575A1
The present invention relates to a method for treating anemia using a long-acting EPO preparation and, more specifically, to a method for treating an anemia patient through verification of the safe and long-acting optimum effective dosag...  
WO/2016/112381A1
Provided are methods of treating a disease or condition characterized by a deficiency of or a defect in an iron transporter using a small molecule. For example, the method may increase transepithelial iron transport, or it may increase i...  
WO/2016/110269A1
Disclosed herein are methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of Physalin to alleviate or ameliorate sym...  
WO/2016/107605A1
The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically ac...  
WO/2016/109774A1
Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., h...  
WO/2016/106626A1
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...  
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/105535A3
Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rsl421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-ob...  
WO/2016/104617A1
This compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity. Consequently, this compound can be a therapeutic agent for Axl-related diseases, for example, cancers such as acute my...  
WO/2016/104451A1
The present invention relates to a compound represented by the following general formula (1) [wherein X represents an oxygen atom, an imino group, a sulfur atom, sulfinyl, or sulfonyl, R1, R2, and R3 each independently represent a hydrog...  

Matches 601 - 650 out of 51,566